GlobeNewswire by notified

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer

Share

Jeito Capital co-leads EUR 50 million financing inCatalYm, a clinical-stage biopharma companydeveloping novel immunotherapies for patients with cancer

  • Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital
    • CatalYm is developing a new class of anti-cancer immunotherapies, which have already demonstrated initial promising clinical results in advanced-stage solid tumor patients
    • Jeito Capital strengthens its strong and diversified portfolio with first German investment

Paris, France, November 22nd2022 - Jeito Capital ("Jeito"), a leading independent international private equity firm dedicated to healthcare and biopharma, announced today that it has co-led a EUR 50 million Series C financing round in CatalYm, a clinical-stage biopharmaceutical company developing novel immunotherapies to fight cancer. The oversubscribed financing was co-led by Brandon Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures, and Coparion. CatalYm was founded in 2016 as a spin-off from Würzburg University and is based in Munich (Germany).

CatalYM’s lead candidate, visugromab is a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). It is currently in Phase 2 clinical studies in patients with solid tumors that are relapsed/refractory to prior anti-PD1/-PD-L1 treatment. GDF-15 acts as a key regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumor tissue.

Proceeds from the financing will primarily be used to expand the Phase 2 clinical development program of visugromab. This expansion is based on convincing efficacy and durability results in advanced, last-line patients in Phase 1 and continued positive clinical responses in the ongoing GDFATHER-2 trial (GDF-15 Antibody-mediaTed Human Effector cell Relocation Phase 2). The expanded Phase 2 clinical studies will enroll patients at clinical centers in Europe and the United States.

Jeito selected CatalYm in line with its investment strategy to support the development of the most promising European Biopharma with growth and acceleration potential. Dr. Andreas Wallnoefer, Partner at Jeito Capital will join CatalYM’s Board of Directors.

Throughout 2022, Jeito has continued to build a portfolio of innovative companies across diverse therapeutic areas and across stages of development with the strong potential to improve the lives of patients. With CatalYm, Jeito makes its first investment in Germany, which has a very dynamic and internationally recognized biopharma ecosystem. Jeito closed its Jeito I fund at €534 million in September 2021 and has to date invested in high-quality biopharma companies with the potential to become market leaders in France, Belgium, Denmark, Switzerland, the UK and the US.

Dr Rafaèle Tordjman, MD, PhD,Founder and CEO of Jeito, commented: “We are thrilled to co-lead this new round of financing in CatalYm to further accelerate its clinical development and support its world leading research for the benefit of severely ill patients with no satisfying therapeutic solution. Jeito is committed to supporting and accelerating the development of the most promising European biopharma companies. CatalYm has the potential of growth and acceleration for patients, which is a core value for Jeito. Jeito selected this clinical stage company that has a promising new therapy approach to treat cancer, which has already demonstrated the first clinical signs of activity for severe relapsed patients. We look forward to working with the experienced CatalYm team.”

Dr. Andreas Wallnoefer, Partner at Jeito, added: “Visugromab has shown promising results in enhancing the immune response to fight cancer in its first clinical trials, resulting in several impressive responses in patients with advanced tumors and last line treatments. The drug has great potential to improve patients’ lives and become part of cancer immune therapy regimens given its important efficacy profile and good tolerability.”

Dr. Phil L’Huillier, Chief Executive Officer at CatalYm, concluded: “The success of our Series C financing, based on strong clinical data, is a further validation that visugromab is emerging as a new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape. We deeply value the commitment of our new and existing investors, which will enable further clinical development moving our lead program towards pivotal studies.”

About Jeito Capital

Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports entrepreneurs through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

@Jeito_lifeLinkedInFor more information, please visit www.jeito.life, or follow @Jeito_life on Twitter or LinkedIn.
About CatalYm

CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment. We are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in non-responsive tumors. CatalYm’s lead program visugromab is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment horizon for current and future immunotherapies.

About visugromab (CTL-002)

Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 secretion by the tumor has been shown to prevent T cell migration into the tumor and suppresses T cell function and the adaptive immune response in the tumor microenvironment. This enables the tumor to evade the immune system and become resistant to standard of care and current immunotherapy approaches such as checkpoint inhibitors. Visugromab counteracts these immuno-suppressive mechanisms by neutralizing GDF-15, enhancing the infiltration of immune cells into the tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and NK cells.

For further information please contact:

Jeito Capital
Rafaèle Tordjman
Assia Mouhout, EA
assia@jeito.life
Tel : +33 6 76 49 37 94

Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam
Jeito@consilium-comms.com
Tel: +44 (0) 20 3709 5700

Marion Bougeard
marion@achto-conseil.fr
Tel : +33 6 76 73 57 31

CatalYmGmbH
Dr. Phil L’Huillier, CEO
info@catalym.com

Trophic Communications
Dr. Stephanie May
Phone: +49 171 185 56 82
catalym@trophic.eu

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

XPENG announces dealer partnerships in UAE, Egypt, Azerbaijan, Jordan and Lebanon22.2.2024 02:30:00 CET | Press release

XPENG, a leading Chinese smart electric vehicle company, announces dealer partnerships in UAE, Egypt, Azerbaijan, Jordan and Lebanon.Through the partnerships, XPENG will bring its EVs to local consumers within each region with branded showrooms and start-to-end customer support throughout the buying process.The partnerships mark several "firsts" for XPENG on its road to globalisation as it aspires to become a leading player in the EV sector. GUANGZHOU, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces its latest long-term strategic partnership with UAE dealership group Ali&Sons. Brian Gu, Vice Chairman and President of XPENG with H.E. Ali bin Khalfan Al Mutawa Al Dhaheri, Founder and Chairman of Ali&Sons. As part of XPENG's international expansion plans, a growing list of new partners from XPENG's strategic markets have joined XPENG in bringing the b

Tenaris Announces 2023 Fourth Quarter and Annual Results21.2.2024 22:27:52 CET | Press release

The financial and operational information contained in this press release is based on audited consolidated financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS Accounting Standards. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Free Cash Flow, Net cash / debt and Operating working capital days. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) today announced its results for the fourth quarter and year ended December 31, 2023 with comparison to its results for the fourth quarter and year ended December 31, 2022. Summary of 2023 Fourth Quarter Results 4Q 20233Q 2023 4Q 2022 Net sales ($ million)3,4153,2385%3,620(6%)Operating income ($

Standard Lithium to Participate in Upcoming Industry Conferences21.2.2024 22:05:14 CET | Press release

VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced senior leadership participation in the following upcoming industry conferences: Event BMO 33rd Global Metals, Mining and Critical Minerals ConferenceDateFebruary 26 – 28, 2024PresentationRobert Mintak, CEO and Director, February 27 - 10:45 to 11:00am ETEvent BofA Global Agriculture and Materials Conference 2024DateFebruary 27 – 29, 2024PanelLithium Panel Discussion featuring Robert Mintak, CEO and Director, February 29 – 8:20 to 9:00am ETEvent 36th Annual Roth ConferenceDateMarch 17 – 19, 2024 Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their BMO, Bank of America, or Roth representative or Standard Lithium Investor Relations at investors@standardlithium.com. About Standard Lithium Ltd. Standa

Lantronix Announces Percepxion™, Its New Cloud Software Platform for IoT Devices21.2.2024 22:05:00 CET | Press release

Percepxion™ comes pre-configured in Lantronix’s gateways, routers, trackers and switches to accelerate IoT edge device deployments IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions, today announced Percepxion™, its new Cloud IoT Edge Solutions platform. Percepxion is pre-configured into Lantronix’s award-winning IoT gateways, routers, trackers and switches to provide secure, comprehensive device lifecycle management. The Percepxion platform efficiently scales edge deployments from regional to global and is managed through an intuitive single pane of glass. “The Percepxion platform provides our customers with an easy-to-deploy IoT solution that comes pre-configured on our connect and compute products,” said Jacques Issa, vice president of Marketing at Lantronix Inc. “Percepxion’s multi-tenant feature enables a B2B solution, generating incremental revenue streams for our end customers.” Remote inst

Amaroq publishes a Supplementary Prospectus in connection with Fundraising21.2.2024 19:09:16 CET | Press release

TORONTO, ONTARIO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- ("Amaroq" or the "Corporation" or the "Company") Amaroq publishes a Supplementary Prospectus in connection with Fundraising TORONTO, ONTARIO – 21 February 2024 – Amaroq Minerals Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ), an independent mining company with a substantial land package of gold and strategic energy transition mineral assets in Southern Greenland, announces publication of a Supplementary Prospectus, consisting of a Supplement to the Registration Document dated 12 September 2023 and a Securities Note, along with a Summary, all dated 21 February 2024, related to fundraising, details of which were disclosed in announcements on 12 and 13 February 2024. The Supplementary Prospectus dated 21 February 2024, has been approved by the Financial Supervisory Authority of the Central Bank of Iceland. The Supplementary Prospectus which is written in English, has been published electronically to the company’s website https://www.amaroqminer

HiddenA line styled icon from Orion Icon Library.Eye